Trials / Completed
CompletedNCT00634946
SI-6603 Versus Placebo in Patients With Lumbar Disc Herniation
A Multicenter, Randomized, Double-blind Recommended Dose-finding Study of SI-6603 in Patients With Lumbar Disc Herniation (Phase II/III Study)
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 195 (actual)
- Sponsor
- Seikagaku Corporation · Industry
- Sex
- All
- Age
- 20 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether SI-6603 is effective in the treatment of lumbar disc herniation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SI-6603 | SI-6603 is administrated into the nucleus pulposus of an intervertebral disc. |
| DRUG | Placebo | Placebo is administrated into the nucleus pulposus of an intervertebral disc. |
Timeline
- Start date
- 2008-01-01
- Primary completion
- 2009-11-01
- Completion
- 2010-08-01
- First posted
- 2008-03-13
- Last updated
- 2023-03-23
Locations
8 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT00634946. Inclusion in this directory is not an endorsement.